STABILIZED EXTERNAL PREPARATION COMPRISING THYMOSIN BETA 4 AS AN ACTIVE INGREDIENT

Abstract

The present invention relates to a stabilized external preparation comprising thymosin beta 4 (T4) as an active ingredient. More specifically, the present invention relates to a therapeutically effective external preparation with improved stability and biological activity of T4. The preparation according to the present invention provides T4 in a stable state by maintaining the biological activity of T4 and minimizing the generation of T4 sulfoxide through oxidization reactions and multimers through aggregation.

Claims

1.-15. (canceled)

16. An external preparation comprising a polypeptide selected from the group consisting of thymosin beta 4 (T4), T4 isoforms having the biological activity of T4, analogues thereof, derivatives thereof, an N-terminal variant of T4 having the biological activity of T4, a C-terminal variant of T4 having the biological activity of T4, LKKTET of SEQ ID NO: 1 or a conservative variant thereof, LKKTNT of SEQ ID NO: 2 or a conservative variant thereof, and combinations thereof; phosphate as a buffer; an additive; and a viscosifier, wherein the additive is selected from the group consisting of disodium-EDTA dihydrate, trehalose, propylene glycol and combinations thereof, and the viscosifier is selected from the group consisting of polyvinyl alcohol, carboxymethyl cellulose, hydroxypropyl methyl cellulose, carbomer, and combinations thereof.

17. The external preparation of claim 16, wherein the additive is selected from the group consisting of disodium-EDTA dihydrate, propylene glycol and combinations thereof; and the viscosifier is carboxymethyl cellulose.

18. The external preparation of claim 16, wherein the polypeptide is comprised in a concentration of 0.001 to 100 mg/ml.

19. The external preparation of claim 16, wherein the additive is comprised in a concentration of 0.01 to 100 mg/ml.

20. The external preparation of claim 19, wherein the additive comprises disodium-EDTA dihydrate and the disodium-EDTA dihydrate is comprised in a concentration of 0.05 to 2.00 mg/ml.

21. The external preparation of claim 19, wherein the additive comprises trehalose and the trehalose is comprised in a concentration of 1 to 50 mg/ml.

22. The external preparation of claim 19, wherein the additive comprises propylene glycol and the propylene glycol is comprised in a concentration of 1 to 100 mg/ml.

23. The external preparation of claim 16, wherein the viscosifier is comprised in a concentration of 1 to 100 mg/ml.

24. The external preparation of claim 23, wherein the viscosifier comprises polyvinyl alcohol and the polyvinyl alcohol is comprised in a concentration of 1 to 40 mg/ml.

25. The external preparation of claim 23, wherein the viscosifier comprises carboxymethyl cellulose and the carboxymethyl cellulose is comprised in a concentration of 1 to 50 mg/ml.

26. The external preparation of claim 23, wherein the viscosifier comprises hydroxypropylmethyl cellulose and the hydroxypropylmethyl cellulose is comprised in a concentration of 1 to 100 mg/ml.

27. The external preparation of claim 23, wherein the viscosifier comprises carbomer and the carbomer is comprised in a concentration of 2 to 35 mg/ml.

28. The external preparation of claim 16, wherein the pH of the preparation is in a range of 5 to 6.

29. The external preparation of claim 16, wherein the viscosity (cP) of the preparation is in a range of 3 to 100,000 at 25 C.

30. The external preparation of claim 16, wherein the preparation is formulated into a form of a gel, a cream, a paste, an ointment, a liniment, a lotion, a hydrogel or an aerosol.

31. A method for treating skin damage through wound closure and tissue regeneration, comprising administering the external preparation of claim 16 to the skin of a subject.

32. The method of claim 31, wherein skin damage is pressure ulcer, foot ulcer, epidermolysis bullosa, oral mucositis, or hidradenitis suppurativa.

33. A method for treating skin damage through wound closure and tissue regeneration, comprising contacting the external preparation of claim 16 into the skin tissue of a subject.

34. A method for treating an inflammation or ulcer of the skin, comprising administering the external preparation of claim 16 to the skin of a subject.

35. The method of claim 34, wherein an inflammation or ulcer of the skin is pressure ulcer, foot ulcer, epidermolysis bullosa, oral mucositis, or hidradenitis suppurativa.

Description

DESCRIPTION OF DRAWINGS

[0012] FIG. 1 is a graph which shows the stability of T4 of the external preparation according to the present invention depending on the pH.

BEST MODE FOR CARRYING OUT THE INVENTION

[0013] The present invention will be described in further detail.

[0014] An aspect of the present invention may provide an external preparation comprising a polypeptide selected from the group consisting of thymosin beta 4 (T4), T4 isoforms having the biological activity of T4, analogues thereof, derivatives thereof, an N-terminal variant of T4 having the biological activity of T4, a C-terminal variant of T4 having the biological activity of T4, LKKTET represented by SEQ ID NO: 1 or a conservative variant thereof, LKKTNT represented by SEQ ID NO: 2 or a conservative variant thereof and combinations thereof; phosphate as a buffer; an additive; and a viscosifier, wherein the additive is selected from the group consisting of disodium-EDTA dihydrate, trehalose, propylene glycol and combinations thereof, and the viscosifier is selected from the group consisting of polyvinyl alcohol, carboxymethyl cellulose, hydroxypropyl methyl cellulose, carbomer, and combinations thereof.

[0015] Most preferably, the external preparation may comprise an additive selected from the group consisting of disodium-EDTA dihydrate, propylene glycol and combinations thereof, and carboxymethyl cellulose as a viscosifier.

[0016] The preparation may comprise distilled water or deionized water as a carrier, and may preferably comprise distilled water.

[0017] Most preferably, the polypeptide is thymosin beta 4, and the thymosin beta 4 may be a protein having the amino acid sequence represented by SEQ ID NO: 3.

[0018] The term thymosin beta 4 used herein refers to a protein that is also referred to as T4, which is a 4.9 kDa polypeptide composed of 43 amino acids that was initially isolated from the thymus gland and found in various types of tissue. The protein is up-regulated during in vitro migration and differentiation of endothelial cells, and a variety of thymosin T4 isoforms have been identified.

[0019] The term conservative variant used herein refers to a variant wherein an amino acid residue has been substituted by a different but biologically similar residue. Examples of substitutions in the conservative variants include substitution of other residues by the hydrophobic residues, e.g., isoleucine, valine, leucine or methionine, and substitution of other residues by polar residues, for example, substitution of lysine by arginine, aspartic acid by glutamic acid, or asparagine by glutamine.

[0020] The T4 according to the present invention may have sequence homology of approximately 70%, 75% or 80% or more with known amino acid sequence of T4. The T4 according to the present invention may be applied to an N-terminal variant and a C-terminal variant of wild type T4. More specifically, it may be a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a conservative variant thereof, a polypeptide having the amino acid sequence of SEQ ID NO: 2 or a conservative variant thereof. T4 isoforms include, for example, T4.sup.ala, T9, T10, T11, T12, T13, T14 and T15. Like T4, the T10 and T15 isoforms, as well as a T4 splice-variant, appear to sequester actin. T4, T10 and T15, as well as other isoforms, share the amino acid sequence LKKTET, which appears to be involved in mediating actin sequestration or binding.

[0021] The activity of T4 isoforms is associated with regulation of the actin polymerization mechanism. -thymosins appear to depolymerize F-actin by sequestering free G-actin. Accordingly, it appears that the ability of T4 to modulate actin polymerization reactions is associated with the activity of binding to actin or sequestering the same through the LKKTET sequence. Accordingly, as with T4, other proteins, including T4 isoforms, which have the amino acid sequence LKKTET and bind to or sequester actin or modulate actin polymerization reactions may, as explained in the present application, be used alone or in combination with T4.

[0022] The external preparation may comprise such polypeptides in a concentration of 0.001 to 100 mg/ml, 0.01 to 10 mg/ml, or preferably, 0.1 to 5 mg/ml.

[0023] Also, the external preparation may comprise phosphate as a buffer. A buffer may be included to keep the chemical properties of the preparation as consistent as possible despite exposure to external influences or the addition of acids or bases. Especially, by using phosphate as a buffer in the external preparation, the formation of oxidized T4 and other impurities can be minimized. Meanwhile, as a buffering agent, acetate, citrate, histidine, hydrogen carbonate, gluconate, propionate or tromethamine (TRIS) buffers, etc., may be included additionally.

[0024] Also, the external preparation may comprise T4 and buffer in a weight ratio of 1:30 to 2:1 or 1:15 to 1:1.

[0025] Additives such as disodium-EDTA dihydrate or EDTA, trehalose, and propylene glycol, etc. may be included in order to further improve the storage stability of the external preparation and propylene glycol or a mixture of propylene glycol and disodium-EDTA dihydrate is most preferable.

[0026] The external preparation may comprise the additives mentioned above in a concentration of 0.01 to 100 mg/ml, and the concentration may vary depending on the type of an additive substance.

[0027] Specifically, disodium-EDTA dihydrate may be contained in a concentration of 0.05 to 2.00 mg/ml, 0.07 to 1.0 mg/ml, or preferably, 0.1 to 0.5 mg/ml. Also, trehalose may be contained in a concentration of 1 to 50 mg/ml, 2 to 30 mg/ml, or preferably, 5 to 20 mg/ml. Also, propylene glycol may be contained in a concentration of 1 to 100 mg/ml, 2 to 50 mg/ml, or preferably, 5 to 20 mg/ml.

[0028] Also, the external preparation may comprise, among the additives mentioned in the above, propylene glycol and disodium-EDTA dihydrate in a weight ratio of 500:1 to 1:1, 300:1 to 2:1, 250:1 to 20:1 or 100:1 to 50:1. Also, the external preparation may comprise propylene glycol and trehalose in a weight ratio of 20:1 to 1:20, 10:1 to 1:10 or 3:1 to 1:3. Also, the external preparation may comprise trehalose and disodium-EDTA dihydrate in a weight ratio of 100:1 to 1:1, 50:1 to 2:1, 25:1 to 5:1 or 20:1 to 10:1.

[0029] Meanwhile, the viscosifier may be comprised to adjust the viscosity of the external preparation and to minimize the formation of oxidized T4 and other impurities. Examples of the viscosifier may include polyvinyl alcohol, cellulose derivatives such as carboxymethyl cellulose and hydroxypropyl methyl cellulose and carbomer, etc., among which carboxymethyl cellulose is most preferable.

[0030] The external preparation may comprise the viscosifiers mentioned above in a concentration of 1 to 100 mg/ml, and the concentration may vary depending on the type of a viscosifier.

[0031] Specifically, the polyvinyl alcohol may be contained in a concentration of 1 to 40 mg/ml, 2 to 30 mg/ml, or preferably, 5 to 20 mg/ml. Also, the carboxymethyl cellulose may be contained in a concentration of 1 to 50 mg/ml, 5 to 40 mg/ml, or preferably, 10 to 30 mg/ml. Also, the hydroxypropyl methyl cellulose may be contained in a concentration of 1 to 100 mg/ml, 10 to 100 mg/ml, or preferably, 50 to 100 mg/ml. Also, the carbomer may be contained in a concentration of 2 to 35 mg/ml, 5 to 30 mg/ml, or preferably, 10 to 30 mg/ml.

[0032] Also, the additives and viscosifiers may be contained individually or together, and the additives and viscosifiers may be included together in a weight ratio of 1:500 to 1:1, 1:300 to 2:1, or 1:250 to 3:1.

[0033] Also, the external preparation preferably contains a mixture of propylene glycol and disodium-EDTA dihydrate as an additive and carboxymethyl cellulose as a viscosifier for the sake of T4 stability. Here, the additive and viscosifier are preferably contained in a weight ratio of 1:300 to 1:2.

[0034] Meanwhile, the external preparation may contain a small amount of a preservative agent, which may be, for example, methyl paraben or propyl paraben, alcohols such as chlorobutanol or benzyl alcohol, or guanidine derivatives, and preferably a paraben.

[0035] The pH of the external preparation may be in a range of 4 to 7, 4.5 to 6.5, or 5 to 6. To minimize the formation of T4 sulfoxide, the pH is preferably in a range of 5 to 6, or most preferably, 5.5 to 6.0.

[0036] Also, the viscosity (cP) of the external preparation may be in a range of 3 to 100,000 at 25 C., and may be adjusted within this range depending on the dosage form while maintaining the stability of the T4.

[0037] The formulation of the external preparation may be a gel, a cream, a paste, an ointment, a liniment, a lotion, a hydrogel or an aerosol.

[0038] The external preparation according to the present invention may be applicable to a subject in need of treatment of skin wounds such as epidermal injury, etc., for example, mammalian animals, and more specifically, humans, but not limited thereto.

[0039] Further, the present invention may provide a method for treating an inflammation or ulcer of the skin, comprising administering the external preparation to the skin of a subject. Specific examples of the inflammation or ulcer may include pressure ulcer, foot ulcer, epidermolysis bullosa, oral mucositis, hidradenitis suppurativa, etc., but not limited thereto.

[0040] The present invention may provide a method for treating an inflammation or ulcer of the skin, comprising contacting the external preparation into the skin tissue of a subject. Specifically, the present treatment method may comprise contacting into the skin tissue a gel, a cream, a paste, an ointment, a liniment, a lotion, a hydrogel or an aerosol which comprises the external preparation by a direct application.

[0041] The external preparation may be administered concurrently or sequentially in combination with another therapeutic agent, and administered in suitably divided doses several times for a certain period. Specifically, the external preparation may be administered as dose frequency between once a week and twice a day.

[0042] The external preparation of the present invention is preferably administered transdermally, and it may be administered via parenteral or intranasal route, or through a mucous membrane, but not limited thereto.

[0043] Further, the present invention may provide a method for treating skin damage through wound closure and tissue regeneration, comprising administering the external preparation to the skin of a subject.

[0044] Specific administration methods and routes of the treatment method of skin damage are same as described above in the treatment method of an inflammation or ulcer of the skin.

[0045] Further, the present invention may provide a use of the external preparation comprising thymosin beta 4 as an active ingredient for use in the prevention or treatment of skin inflammation and ulcer.

[0046] Further, the present invention may provide a use of the external preparation comprising thymosin beta 4 as an active ingredient for use in the prevention or treatment of skin damage.

MODE FOR THE INVENTION

[0047] Hereinafter, preferred embodiments are provided for further illustration. The following examples are, however, given for the purpose of illustration only, and are not intended to limit the scope of the present invention.

Experimental Example 1: Confirmation of T4 Stability Depending on pH

[0048] The experiments for the confirmation of stability depending on pH were carried out over 6 days at 60 C. For pH values 2, 3, 6, 7, and 8, phosphate was used as a 50 mM buffer. For pH 4 and 5, acetate was used, while sodium bicarbonate was used for pH 9. Samples were prepared so that approximately 0.2 mg/mL of T4 could be included in each buffer, and some were autoclaved. Residual T4 was measured in each sample, and the results are shown in FIG. 1. As shown in FIG. 1, it can be found that the pH range where T4 stability is best is from pH 5 to 6.

Experimental Example 2: Comparison of T4 Stability Depending on the Kind of Buffer

[0049] T4 was dissolved in each of the 30 mM buffers indicated in Table 1 below in a concentration of 1 mg/ml, then stored for 1 week at 40 C. Then reverse phase HPLC was employed to measure changes in T4 content and the total amount of the peaks for impurities. T4 content was measured by comparing the peak areas of the initial sample and the sample stored at 40 C. for 7 days with the peak area of the standard, and the rate of reduction was shown as a percentage (%) of (initial contentcontent after 1 week) initial content.

[0050] T4 oxides (methionine oxidized compound) were measured by comparing the peak area of the methionine oxides based on all peak areas shown during the HPLC analysis as a percentage (%). The rate of increase was shown as the ratio of (area for oxides after 1 week in %initial area for oxides in %) initial area for oxides in %.

[0051] Total impurities were measured by comparing the area of the peaks excluding that for T4 based on all peak areas shown during the HPLC analysis as a percentage (%). The rate of increase was shown as the ratio of (area for total impurities after 1 week in %initial area for total impurities in %) initial area for total impurities in %.

TABLE-US-00001 TABLE 1 Oxides Content (mg/mL) (Methionine oxidation) Total impurities Buffer Initial 1 week, Rate of Initial 1 week, Rate of Initial 1 week, Rate of No. Type* pH value 40 C. reduction value 40 C. increase value 40 C. increase 1 Phosphate 5.0 0.96 0.90 6.2% 0.38% 0.51% 0.34 0.40% 4.12% 9.30 2 Phosphate 5.5 0.97 0.92 5.2% 0.46% 0.59% 0.28 0.44% 3.70% 7.41 3 Phosphate 6.0 0.99 0.93 6.1% 0.60% 0.70% 0.17 0.37% 3.60% 8.73 4 Histidine 5.0 0.98 0.53 45.9% 0.50% 2.57% 4.13 0.42% 29.20% 68.52 5 Histidine 5.5 1.00 0.44 56.0% 0.31% 0.82% 1.65 0.32% 49.10% 152.44 6 Histidine 6.0 0.99 0.92 7.1% 0.29% 0.90% 2.10 0.32% 6.42% 19.06 7 Citrate 5.0 0.99 0.92 7.1% 0.26% 1.10% 3.23 0.30% 5.56% 17.53 8 Citrate 5.5 0.99 0.91 8.1% 0.32% 1.07% 2.34 0.40% 4.05% 9.13 *The sources of the reagents used in the respective experiments are as follows. Sodium phosphate dibasic dihydrate: Sigma-Aldrich, Cat#: 71662 Sodium phosphate monobasic monohydrate: Sigma, Cat#: S3522 Histidine: VWR, Cat#: JT2080-5 Citric acid monohydrate: Sigma-Aldrich, Cat#: C1909 Trisodium citrate dihydrate: Sigma-Aldrich, Cat#: S4641

[0052] As shown in Table 1, T4 oxides tended to increase more at lower pH (acid). It was confirmed that phosphate as a buffer could maintain the stability of T4.

Experimental Example 3: Comparison of T4 Stability Depending on the Kind of Additive

[0053] T4 was dissolved in 10 mM phosphate buffer at pH 5.5 in a concentration of 1 mg/ml, and then additives with the contents indicated in Table 2 were dissolved therein. Impurities of the initial state (day 0) in each solution were measured using reverse phase HPLC, and the impurities of each solution stored for 1 week at 40 C. were then measured using reverse phase HPLC.

[0054] The additives were employed with the lowest possible concentration in the range of concentrations generally used for external preparations to investigate the influence on T4 at the lowest additive concentration.

[0055] Total impurities were measured by comparing the area of the peaks excluding that for T4 based on all peak areas shown during the HPLC analysis as a percentage (%). The rate of increase was shown as the ratio of (area for total impurities after 1 week in %initial area for total impurities in %) initial area for total impurities in %.

TABLE-US-00002 TABLE 2 Oxides (Methionine oxidation) Total impurities Concentration Initial 1 week, Rate of Initial 1 week, Rate of No. Additives* (mg/ml) value 40 C. increase value 40 C. increase 1 Propylene Glycol 10 0.34 0.28 0.18 0.52 2.00 2.85 2 Trehalose 10 0.35 0.59 0.69 0.53 2.31 3.36 3 EDTA 2Na 0.5 0.14 0.57 3.07 1.06 4.19 2.95 4 EDTA 2Na + Trehalose 0.5 + 10 0.33 0.69 1.09 1.39 4.31 2.10 5 Propylene Glycol + EDTA 2Na 10 + 0.5 0.44 0.49 0.11 1.31 4.05 2.09 6 Propylene Glycol + Trehalose 10 + 10 0.21 0.61 1.90 1.17 4.41 2.77 7 HPCD 10 0.34 0.57 0.68 0.60 4.60 6.67 8 PEG 40-Stearate 10 0.44 2.36 4.36 0.44 3.17 6.20 9 PEG 400 10 0.41 3.07 6.49 0.41 3.92 8.56 10 Tween 20 0.5 0.20 0.37 0.85 1.43 11.09 6.76 *The sources of the reagents used in the respective experiments are as follows. Propylene Glycol: Aldrich, Cat#: W294004 Trehalose: Sigma-Aldrich, Cat#: T9449 PEG (Polyethyleneglycol) 40-Stearate: TCI, Cat#: P0721 PEG 400: Merck, Cat#: 807485 HPCD: (2-Hydroxypropyl)--cyclodextrin: Aldrich, Cat#: 332607 Tween 20: Croda International Plc. Product Code: SD40271 EDTA 2Na: Disodium ethylenediaminetetraacetate dihydrate: Sigma, Cat#: E6635

[0056] As shown in Table 2, the formation of T4 impurities and oxides was low when propylene glycol, trehalose, and EDTA 2Na were added. Combinations of these also exhibited similar stabilization effects. Meanwhile, HPCD, which is reported to be a peptide stabilizer, did not have effects, and it was confirmed that oxidized T4 increased sharply with PEG-type additives (PEG 40-Stearate, PEG 400), while the total amount of impurities increased significantly with Tween 20.

Experimental Example 4: Comparison of T4 Stability Depending on the Kind of Viscosifier

[0057] T4 was dissolved in 10 mM phosphate buffer at pH 5.5 in a concentration of 1 mg/ml, and then viscosifiers with the contents indicated in Table 3 were dissolved therein. Impurities of the initial state (day 0) in each solution were measured using reverse phase HPLC, and the impurities of each solution stored for 1 week at 40 C. were then measured using reverse phase HPLC.

[0058] Total impurities were measured by comparing the area of the peaks excluding that for T4 based on all peak areas shown during the HPLC analysis as a percentage (%). The rate of increase was shown as the ratio of (area for total impurities after 1 week in %initial area for total impurities in %) initial area for total impurities in %.

TABLE-US-00003 TABLE 3 Oxides (Methionine oxidation) Total impurities Concentration Initial 1 week, Rate of Initial 1 week, Rate of No. Viscosifiers* (mg/ml) value 40 C. increase value 40 C. increase 1 PVA 10 0.31 1.34 3.32 0.46 2.39 4.18 2 HPMC 10 0.27 0.46 0.71 0.38 2.05 4.39 3 CMC 10 0.31 0.47 0.52 0.48 2.27 3.73 4 Carbomer Homopolymer Type B 10 0.41 0.75 0.83 0.35 2.86 7.16 5 Hyaluronate Na 5 0.35 1.13 2.23 0.74 7.12 8.62 6 Xanthan 10 0.34 2.94 7.63 0.34 4.82 13.16 7 Polyvinylpyrrolidone 20 0.87 30.18 33.69 0.87 31.18 34.84 8 Methyl cellulose (4000 cP) 10 0.24 0.63 1.61 0.24 3.33 12.86 9 Polycarbophil 10 0.31 0.82 1.65 0.58 11.31 18.50 10 Gellan gum 10 0.38 1.24 2.26 0.64 5.01 6.83 *The sources of the reagents used in the respective experiments are as follows. PVA (Polyvinyl alcohol): Sigma-Aldrich, Cat#: 81365 HPMC (Hydroxypropyl methylcellulose): Shin-Etsu, Product ID: Metolose 90SH-100000SR CMC (Sodium Carboxymethyl cellulose): Ashland, Cat#: 414483 Carbomer Homopolymer Type B: Mutchler Inc. Product Code: Carbopol Mutchle Hyaluronate Na: Bloomage Freda Biopharma Co. Ltd., Product code: HA-EP1 Xanthan: CP Kelco U.S. Inc., Material #: 10054521 Polyvinylpyrrolidone: Alfa Aesar, Cat#: A14315 Methyl cellulose: Sigma, Cat#: M0512 Polycarbophil: Mutchler Inc. Product Code: Noveonhler I Gellan gum: Sigma-Aldrich, Cat#: G1910

[0059] As shown in Table 3, T4 tended to be stable when the samples contained additives such as polyvinylalcohol, Carbomer Homopolymer Type B, and cellulose-type additives such as HPMC and CMC. Meanwhile, T4 oxides increased sharply in the samples containing polyvinylpyrrolidone, while the total amount of impurities was significantly increased in the samples containing xanthan and polycarbophil than the cases where other additives were added. As for gellan gum, a precipitate that cannot be found by HPLC analysis was formed.

Preparation Examples 1 to 4: Preparation of an External Preparation

[0060] Sodium phosphate dibasic, sodium chloride, sodium carboxymethyl cellulose (or HPMC, carbomer) and distilled water were placed in a stainless steel vessel and stirred until completely dissolved. EDTA 2Na, trehalose or propylene glycol was slowly added thereto and stirred. Then, a 10 diluted hydrochloric acid solution was used to adjust the pH to 5.7. T4 was added to the solution, and the pH was measured to confirm that it was in a range of 5 to 6.0. The air bubbles in the gel prepared by depressurizing the vessel were removed to prepare the external preparation according to the examples having the compositions indicated in Table 4.

TABLE-US-00004 TABLE 4 Substance Example 1 Example 2 Example 3 Example 4 Thymosin 4 172 mg Propylene Glycol 5.75 g 5.75 g Trehalose 5.75 g EDTA 2Na 2H.sub.2O 63 mg 63 mg Carboxymethylcellulose 14.4 g 14.4 g Na HPMC K4M 43.9 g Carbomer Homopolymer 11.0 g Type B Sodium Phosphate 805 mg Dibasic Sodium Chloride 4.03 g Sterile Water for Amount required to prepare total Injection amount of 548 g 1:10 HCl Solution pH adjusted to 5.7 0.1

[0061] The T4 content and viscosities of the external preparation according to Examples 1 to 4 were measured and shown in Table 5.

TABLE-US-00005 TABLE 5 Substance Example 1 Example 2 Example 3 Example 4 Content (%) 106.2 80.3 76.3 102.1 Total impurities (%) Not detected 0.64 0.78 0.37 pH 5.71 5.78 5.84 5.74 Viscosity (cP) 3394 3621 3745 2516

[0062] Whereas viscosity was at levels suitable for use as an external preparation in all examples, the result of content measurement revealed that the content of the preparations of Examples 2 and 3 was lower than Examples 1 and 4. This may be due to the fact that the T4 was not effectively eluted from the prepared preparation.

Experimental Example 5: Confirmation of Stability of the External Preparation

[0063] To confirm the stability of the external preparations of Examples 1 and 4, stability test was carried out over 12 months under the conditions of 2-8 r/ambient relative humidity and 25 C., 60% relative humidity. The results were shown in Tables 6 to 9.

TABLE-US-00006 TABLE 6 Stability test for the external preparation of Example 1 (2-8 C./ambient relative humidity) Test item Initial value 3 M 6 M 9 M 12 M 18 M 21 M Content (%) 106.2 94.4 93.2 91.1 95.5 95.3 94.6 Total impurities (%) Not detected 2.98 3.33 3.24 3.90 4.16 4.46 Viscosity (cP) 3394 3604 3945 3486 4168 4194 3552

TABLE-US-00007 TABLE 7 Stability test for the external preparation of Example 1 (25 C./60% relative humidity) Test item Initial value 1 M 2 M 3 M 6 M 9 M 12 M Content (%) 106.2 101.0 100.8 99.1 96.5 93.7 79.9 Total impurities (%) Not detected 2.82 3.21 3.31 6.16 6.10 19.49 Viscosity (cP) 3394 3460 3329 3525 4128 3984 4272

TABLE-US-00008 TABLE 8 Stability test for the external preparation of Example 4 (2-8 C./ambient relative humidity) Test item Initial value 3 M 6 M 9 M 12 M 18 M 24 M Content (%) 102.1 101.3 102.2 105.2 103.3 107.0 105.9 Total impurities (%) 0.37 1.66 1.30 1.14 3.24 0.92 2.95 Viscosity (cP) 2516 2660 2818 2621 2804 2857 2713

TABLE-US-00009 TABLE 9 Stability test for the external preparation of Example 4 (25 C., 60% relative humidity) Test item Initial value 1 M 2 M 3 M 6 M 9 M 12 M Content (%) 102.1 101.4 103.1 101.0 102.8 105.9 105.9 Total impurities (%) 0.37 1.38 2.70 3.15 2.52 3.46 5.37 Viscosity (cP) 2516 2778 2739 2634 2883 3054 2795

[0064] As shown in Tables 6 and 7, the external preparations of Examples 1 and 4 were found to remain stable enough for medical use for 2 years when stored at 2 to 8 C. Especially, the preparation of Example 4 was found to have superior stability even under the relatively harsh condition of 25 C., 60% relative humidity.

[0065] An embodiment of the present invention has been described in the above, but a person having ordinary skill in the art will be able to apply various modifications and changes to the present invention without departing from the spirit of the present invention as indicated in the attached claims by including, modifying, deleting or adding components, and such shall be said to be included within the scope of the present invention.